Coverage criteria and the evidence standard. How payers and HTA bodies evaluate access and step-edits.
CMS routes all four approved 1L NSCLC IO agents through Part B buy-and-bill at ASP+6%, but PD-L1 assay requirements split coverage into three distinct biomarker-testing tiers.
Why the orphan-drug exclusion shields anti-C5 agents from IRA negotiation, ICER's 2024 value verdict on iptacopan, and Part B vs Part D routing.
Tafamidis is shielded from IRA negotiation by the orphan-drug exclusion — ICER judged its ~$268K price ~85–95% too high, and acoramidis plus pending generics are the real net-price levers.
Specialty-tier prior authorization, prophylaxis above $300K/patient/yr, ICER 2018/2021 value-based benchmarks and no-concurrent-acute-agent rules.
How US payers gate the five FDA-approved IgAN therapies — biopsy, proteinuria and RAS-blockade step-through, the Filspari REMS, Part D routing and the ICER 2026 assessment.
ICER priced efgartigimod's value at $18,300 to $28,400 a year, under half its ~$418,400 launch cost, and that gap is hardening into a three-tier FcRn-to-C5 step-edit across US commercial plans.
IV enzyme replacement buy-and-bill under Part B vs oral SRT under Part D, the CYP2D6 PA gate, and generic miglustat.
Zolgensma's $2.125M one-time cost, outcomes-based Medicaid contracts, and Part B vs Part D routing across three SMA modalities.
Gene-therapy access at $2.2–3.1M, the CMS Cell & Gene Therapy Access Model, VOC-freedom endpoints, and the hydroxyurea step-edit.
Fintepla's list price runs roughly 3x Epidiolex, and payer scrutiny turns on high WAC against a small, severe paediatric population.
A genetic test gates oral migalastat, IV enzyme replacement sits in Part B, and Fabrazyme has no US biosimilar — though the IRA's orphan-drug exclusion shields it from Medicare price negotiation.
Pompe ERT costs near $400,000 a year in Part B, Pombiliti + Opfolda splits into two simultaneous prior authorisations across Part B and Part D, and Pompe remains the only major rare-disease ERT category ICER has never reviewed.
Sutimlimab (Enjaymo) is a ~$260K+/year Part B IV biologic in a few-thousand-patient population — and not cost-effective at the current price.
Topical-then-biologic step-therapy, JAK black-box PA gates, ICER's dupilumab-aligned and JAK-discount verdicts, and why Dupixent is not IRA-selected.
Why Rezdiffra's $47,400 WAC lands inside ICER's value range, why the IRA reset hits semaglutide first, and how Part D routing shapes MASH access.
Type 2 Diabetes is IRA ground zero: three orals negotiated for 2026, semaglutide at $274 for 2027, and the class price anchor reset.
Why CMS's coverage-with-evidence-development registry, not IRA negotiation, is the anti-amyloid access gate, plus ICER's below-value verdict and Part B routing.
Why Medicare covers Wegovy only for cardiovascular risk, how the IRA's IPAY 2027 semaglutide price applies across the franchise, and ICER's 2025 'high value' verdict.
COPD access is a pharmacy-benefit story: inhalers and biologics run through Medicare Part D and commercial PBMs, not medical coverage. Step edits gate the base, an eosinophil threshold gates the biologic, and the IRA is reshaping both price exposure and negotiation risk.
US access to plaque psoriasis biologics is gated by step therapy and reshaped by two forces landing together: Inflation Reduction Act price negotiation on Stelara and Enbrel, and biosimilar erosion of adalimumab and ustekinumab.
US access to HR+/HER2- oral therapies runs through Medicare Part D and commercial prior authorization, and the price ceiling is now being set directly by the government: palbociclib was selected for Medicare negotiation with a 50% cut ($15,741 to $7,871) effective 2027. Newer targeted agents face biomarker-gated coverage and cost-effectiveness ratios far above accepted thresholds.
NPHC's KSA-first coverage model sets the de facto GCC access bar for anti-C5 agents — iptacopan faces a 12-24 month SFDA registration queue before NPHC even evaluates it.
Why the GCC's largest rare-disease programme by patient volume (8,000-10,000 NPHC-managed SCD patients) sits in a commercial vacuum, with crizanlizumab and voxelotor both withdrawn, ahead of 2025-26 gene therapy registration.
NICE's rejection-then-reversal of Zolgensma (2021→2023) established a Long-Term Value Framework precedent that now makes one-time gene therapy the NHS's preferred economic choice for newborn-screened SMA infants.
Both ravulizumab and iptacopan cleared NICE's standard Technology Appraisal route (TA698 and TA1000) at the ordinary £20,000–£30,000/QALY bar — the real payer question is how fast NHS converts patients from IV ravulizumab to oral iptacopan, not which drug got the easier appraisal.
Why NICE recommended both Dravet therapies through standard Technology Appraisal rather than the ultra-rare HSS route, what the Fintepla Cardiac Monitoring Scheme costs the NHS, and why the UK treatment algorithm is now closed to new entrants without a significant clinical edge.
Why GCC tafamidis costs roughly a tenth of its US price yet uptake is limited not by affordability but by Tc-PYP scintigraphy access at fewer than 8 GCC centres.
NHS England's Pompe commissioning-policy continuation criteria define a 45-50 patient switch-eligible cohort for avalglucosidase alfa (NICE TA821) — a manageable NHS budget event, while broader first-line uptake would be a materially larger one.
Agalsidase beta was never formally appraised by NICE, while migalastat's HST4 recommendation (2016) was the first oral mutation-specific rare disease therapy NICE approved; together they underpin an estimated £144M NHS Fabry programme, with a £70-130K/patient/year switch incentive still unrealised at scale.
NICE's SCD gene therapy appraisal, potentially the largest NHS rare disease budget event in history, hinges on an annuity payment model that current NHS SCD management cost cannot yet clearly justify.
NICE's accepted cost-effectiveness case for budesonide (TA937, updated by TA1128) rests on a 5–8 year modelled ESRD delay, and the same mandatory ACEi/ARB gate applied to sparsentan narrows the UK's eligible IgA nephropathy population from 10,000–15,000 to 3,000–5,000 patients.
Why the most effective Dravet agent is the least accessible in the GCC — cannabidiol's Schedule-1-equivalent narcotics classification caps exceptional-import approval at 35-40%.
Why SMA is the most mature rare-disease access model in the GCC — all three modalities NPHC-covered, with Zolgensma's outcomes-based milestone rebate as the GCC-first template other programmes are built to follow.
NICE's June 2025 rejection of efgartigimod (TA1069) leaves UK myasthenia gravis with no NICE-recommended novel agent — eculizumab's own appraisal (TA636) was withdrawn by the manufacturer in 2020 without a cost-effectiveness verdict, and the NHS IVIg cost-offset argument is now the strongest lever for a future resubmission.
Why IgA nephropathy has no NPHC programme at all — access runs entirely through hospital pharmacy committees or private insurance, gated by a biopsy available at fewer than 20 GCC centres.
NICE TA606 commissioned lanadelumab with PAS and 87.5% real-world attack reduction — berotralstat's NICE TA738 recommendation is now tested against that same benchmark.
Why NPHC has a 72%-cost-reduction financial incentive to switch amenable-mutation Fabry patients from ERT to migalastat — and why a single HEK293 assay lab in the entire GCC is the only thing standing in the way.
Why NPHC's well-established Pompe programme still gates avalglucosidase behind a 12-month failed-response switch criterion — and why Sanofi is pursuing NPHC first-line approval to bypass it.
GCC HAE access is structurally two-tier — broad acute coverage, but an NPHC individual-case prophylaxis bar only 30-40% of applicants clear, and private insurance beats the NPHC pathway on speed.
Why generalised myasthenia gravis has no formal NPHC programme — efgartigimod access runs through private insurance (fastest, 1-4 weeks) or hospital pharmacy committees, with NPHC engagement targeted for 2025-2026.
Iptacopan's orphan-drug status let it clear Germany's AMNOG process with an established additional benefit and no comparator dossier at all. Ravulizumab's only PNH-specific G-BA review found no added benefit.
HAS rated iptacopan ASMR III but restricted it to second-line use, while ravulizumab holds SMR important and first-line status. CEPS negotiated iptacopan's price against a manufacturer-estimated population of just 270 patients.
NICE TA696 (May 2021, since updated by TA984) opened NHS commissioning of tafamidis for ATTR-CM at scale — acoramidis’s pending appraisal and vutrisiran’s TA868 access route are the two other decisions defining the UK amyloidosis market.
A PDF access assessment, an Excel coverage and GTN grid, and a PowerPoint readout, with a 45-minute analyst call included.
Coverage and HTA claims are cited to the live policy or assessment document at the point of writing and re-checked before delivery.
Yes. You set the market, payer set and comparators; scope is confirmed on a call before research begins.